Phenotypeca provides novel biologics production strains of the regulatory friendly baker's yeast, Saccharomyces cerevisiae for the production of biologics.
We offer world leading yeast technology to rapidly provide cost-effective production strains optimised for specific biotechnology processes. This is achieved by harnessing the natural diversity in up to a billion different yeast cells to identify those with the ideal phenotypes and performance characteristics for your industrial process conditions.
Working with our customers we aim to improve access to life-saving medicines and promote sustainable manufacturing. With baker's yeast now fully established for the safe and economic production of FDA approved biologics, such as insulins and vaccines, our technology is ideal for taking your bioprocesses to the next level.
S. cerevisiae is already well-established for large-scale cGMP manufacturing of FDA approved biologics at competitive cost-of-goods.
Yeast breeding has a highly successful track-record for strain improvement, which we combine with rational synthetic biology and beneficial phenotypes known from existing large-scale industrial expression platforms.
By selecting candidates from around a billion different strains, we identify the ideal phenotypes and performance characteristics tailored to your industrial process conditions, with scale-up designed in.
High-throughput phenotyping and quantitative trait loci (QTL) analysis is a proven method for strong IP generation.
* Convention on Biological Diversity.Get in touch
If you have any questions, or would like to find out more about our unique processes, please get in touch.